comprehensive -WSS

comprehensive

author：leisure time 2025-09-27 09:40:16 - browse：85

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Sweden knocks USA out of World Cup in penalty kicks

WSS

Many breast cancer patients receive more radiation than needed

Google's generative AI to analyze medical images — and talk to docs

Tuberculosis patients need more than just free medication

FDA clears Verve to begin U.S. study of gene

The problems with dementia villages

Doctors push to include dialysis machines in emergency stockpile

entertainment

comprehensive

leisure time

Psychedelics group wrestles with new pharma identity

NFL doctors' conflicts of interest could endanger players, report says

Drug repurposing or repositioning? The language matters

Results on Novartis prostate cancer therapy could expand its use

In Memoriam: Notable people who died in 2023

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Moonlake's readout produced a cash windfall. Risks remain

Results on Novartis prostate cancer therapy could expand its use

Alkermes shareholders re

STAT Summit: How researchers deal with rejection

focus

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Slovenia has suffered its worst

Doctors are clamoring for more clarity on Paxlovid prescribing

Health tech investors get more selective as pandemic boom fades

Slovenia has suffered its worst

entertainment

focus

knowledge

leisure time